Cystic Fibrosis News Digest — Issue 04

Jasmin Berger, Yin Yu, Julian Berges, et al.

Summary: Researchers studied 26 children aged 2 to 11 years who have cystic fibrosis and carry at least one copy of the most common CF gene variant, known as F508del. They measured how well the faulty CF protein was working — using a sensitive test on a small tissue sample taken from the rectum — before and four months after the children started taking elexacaftor/tezacaftor/ivacaftor (ETI), a combination medicine that helps the CF protein do its job. After four months, the protein's function had been restored to roughly 89–99% of what is seen in people without CF. That level of recovery is substantially higher than the roughly 40% restoration previously recorded in teenagers and adults using the same measurement method. The researchers also found that younger children tended to show greater improvement than older ones.

Why it matters: Restoring the CF protein's function to near-normal levels in young children is an important finding, both scientifically and for families. If this level of recovery holds over time, it raises the possibility that starting ETI early — before organ damage has accumulated — could do more than slow the disease. It might prevent some of that damage from happening at all. The observation that younger children responded better than older ones also strengthens the argument for early treatment and has direct relevance for newborn screening programs and decisions about when to begin therapy.

What to keep in mind: Only 26 children were studied, and results varied considerably from child to child — some responded far less than the group average. The four-month observation period is too short to tell us whether better protein function at the cellular level translates into healthier lungs or other organs over years. The link between age and response is interesting but cannot yet be fully explained; other factors, such as the specific gene variants a child carries or how advanced their disease already is, could partly account for it. Longer studies that track children's health over time are needed to answer these questions. Near-normal protein function is a promising starting point, but it is not the same as a cure.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42785803/

---

Cynthia D Brown, Kevin J Psoter, Kathryn A Sabadosa, et al.

Summary: This study — called HERO-2 — followed 709 people with CF aged 12 and older who were taking ETI, over a period of 12 months. It asked whether people who stopped one or more of their other daily CF treatments — such as airway clearance devices, inhaled antibiotics, or mucus-thinning medicines — had worse lung outcomes than those who kept taking everything. Using a statistical method to account for differences between the groups, the researchers found no significant increase in lung infections or lung function decline among those who had stopped some treatments. Notably, 41.5% of participants had already stopped at least one such treatment on their own before the study began.

Why it matters: ETI has improved health so much for many people with CF that patients and their doctors are asking a natural question: does everyone still need to take all of their other treatments every day? These treatments are time-consuming, burdensome, and expensive. The HERO-2 study is the first to follow people prospectively — tracking them forward in time — to see what happens when some treatments are stopped. The finding that stopping did not appear harmful over 12 months is useful for conversations between patients and their care teams, even though it does not amount to a green light for everyone to start stopping therapies.

What to keep in mind: The study has important limitations to consider. People reported which treatments they had stopped through an app, so the details — exactly which treatments, when they stopped, and how consistently — are not fully known. Twelve months may not be long enough to detect gradual lung decline, particularly in people who are doing well on ETI. People who felt well enough to stop treatments may have been healthier to begin with, and no statistical method can fully account for that. The group studied was recruited through a digital platform, which may not represent people with more severe disease or less access to technology. The study does not prove that stopping treatments is safe — it shows that in this group, over this period, no clear harm was detected. That is a meaningful finding, but more research with longer follow-up and better detail about which treatments are stopped is needed before any broad recommendations can be made.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42554296/

---

Hande Yetişgin, Işıl Bilgiç, Meltem Kürtül Çakar, et al.

Summary: Researchers in Turkey followed 24 children with CF receiving CFTR modulator therapy — and their parents — for 18 months, using established questionnaires to measure anxiety, depression, sleep quality, and quality of life at the start and end of the study. By the end, children showed meaningful improvements in anxiety, depression, and daytime sleepiness. Their parents also reported lower depression, less anxiety, reduced caregiver burden, and better overall quality of life. Scores on a widely used CF quality-of-life measure improved in physical, social, and breathing-related areas for both children and parents.

Why it matters: Living with CF takes a heavy psychological toll on patients and families, and this aspect of the condition has historically received less attention than lung function. If CFTR modulators — which already help breathing and nutrition — also reduce anxiety and depression in children and ease the burden on caregivers, the case for making these medicines widely available becomes even stronger. This study followed people over 18 months, which is longer than most previous work on this question, and used well-recognized measurement tools.

What to keep in mind: With only 24 participants, all from a single hospital in Turkey, it is difficult to know how widely these findings apply. More importantly, the study had no comparison group — there were no CF patients followed over the same period without modulator therapy. Without that comparison, it is impossible to know how much of the improvement was caused by the medicine itself, and how much was due simply to the passage of time, the natural course of the disease, or the extra attention that comes with being in a study. Improvements in physical health over 18 months of treatment could also explain better mental health, independently of any direct effect of the medicine on the brain or mood. Larger studies involving multiple hospitals and a comparison group are needed before firm conclusions can be drawn about whether CFTR modulators directly improve mental health.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42576010/

---

Hiba J Mustafa, Yair J Blumenfeld, Ramen H Chmait, et al.

Summary: This review article brings together current evidence on what happens when pregnant people with CF take CFTR modulator medicines — particularly ETI and a newer combination called vanzacaftor/tezacaftor/deutivacaftor (VTD) — during pregnancy. Studies show that these medicines cross the placenta and reach the developing baby at levels that may be biologically active. Early reports suggest that continuing these medicines during pregnancy can help stabilize the mother's lung health and nutrition. There are also case reports of bowel problems in the unborn baby — a CF complication called meconium ileus — appearing to improve after the mother started or continued modulator therapy. The review also raises concerns, including the risk of falsely reassuring newborn screening results in babies exposed to these medicines before birth, and open questions about the long-term effects on the baby's development.

Why it matters: CF can begin causing damage before birth — conditions like meconium ileus, pancreatic problems, and certain reproductive complications are already present at delivery. The possibility of treating the disease before birth, using medicines that cross the placenta, is a genuinely new frontier. The question of whether to continue these medicines during pregnancy is also immediately practical: because ETI has dramatically improved health and life expectancy, many more people with CF are now becoming pregnant, and their doctors need guidance. There is also an urgent, practical concern: babies exposed to modulators in the womb may test falsely negative on standard newborn CF screening, meaning the disease could be missed unless screening protocols are updated.

What to keep in mind: The evidence reviewed here comes from case reports, small observational studies, animal research, and expert opinion — not from clinical trials designed to test this question directly. Trials in pregnant people are very difficult to conduct for ethical and practical reasons, but the absence of controlled evidence means great caution is warranted. Women who chose to continue their medicines during pregnancy may have been healthier to begin with, making it hard to draw conclusions about outcomes. Eye problems (cataracts) have been observed in some animal studies and require ongoing careful monitoring in humans. The authors appropriately describe treating the unborn baby as an investigational use of these medicines, not a standard recommendation. Long-term follow-up of children born to mothers on these medicines, including careful assessment of brain development, will be essential. The newborn screening problem deserves immediate clinical attention, regardless of broader questions about fetal treatment.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42819752/

---

Diane A Merino, Samuel D Cohen, Nouha Ben Othman, et al.

Summary: Researchers analyzed reports of psychiatric side effects — including sleep problems, mood changes, and suicidal thoughts — that had been submitted by healthcare professionals and patients to two large drug safety databases: France's national pharmacovigilance database (116 cases) and VigiBase, a global database maintained by the World Health Organization (3,407 cases). Reports covered the years 2012 to 2024 and focused on CFTR modulators, mainly ETI. Using a standard method for detecting whether a particular drug is associated with more reports of a certain problem than would be expected by chance, the researchers found that mental health events were over-represented with ETI compared with other drugs in the database. Sleep problems were the most common concern in children; mood disturbances and reports related to suicidality were more common in teenagers. No completed suicides were reported; six suicide attempts were identified in the French database.

Why it matters: Because ETI is now used by a very large number of people with CF, even a rare side effect could affect many people. Mental health concerns had been raised informally before; this analysis is one of the more systematic efforts to look at psychiatric reports across a large dataset and to break down findings by age group. If a real link between ETI and mental health events exists — particularly in children and teenagers — it would have direct implications for how patients and families are counseled when starting the medicine and how they are monitored over time.

What to keep in mind: This type of analysis — looking at voluntary reports submitted to safety databases — is designed to generate signals and hypotheses, not to prove that a medicine causes a problem. There is no way to know how many people are actually taking the medicine and not reporting problems, so it is impossible to calculate a true rate of side effects. Doctors and patients may be more likely to report mental health events for ETI precisely because the question has been raised publicly — a known bias in safety reporting systems. Critically, people with CF already experience significantly higher rates of anxiety and depression than the general population, simply because of what it means to live with a serious illness. It is also possible that dramatic improvements in physical health from ETI allow people to notice or acknowledge mental health difficulties that were previously overshadowed by physical symptoms. This evidence is not a reason to change prescribing, but it is a reasonable basis for structured, routine mental health check-ins as part of CF care — and for properly designed studies with appropriate comparison groups to determine whether a real causal link exists.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42707002/

---

Jonathan H Rayment, Gwyneth Davies, Jonathan M Gaffin, et al.

Summary: The TIMBERLINE trial tested a newer CFTR modulator combination — vanzacaftor-tezacaftor-deutivacaftor (vanza-teza-deuti) — in 67 children aged 2 to 5 years over 24 weeks. All children had gene variants that respond to this class of medicine. The primary question was whether the treatment was safe and well tolerated in this very young age group: no serious side effects related to the treatment were reported, and all 67 children completed the study. Children who switched to vanza-teza-deuti from ETI showed an additional average reduction of 9.6 mmol/L in sweat chloride — a well-established marker of how well the CF protein is working — and 65% reached sweat chloride levels below 30 mmol/L, a threshold associated with near-normal protein function.

Why it matters: Reaching preschool-aged children with effective CF treatment matters because organ damage from CF can begin accumulating in the first years of life, before any symptoms are obvious. Vanza-teza-deuti has already been shown to outperform ETI in older patients; these results suggest the added benefit extends to the youngest children who can be treated. Given how few toddlers can be enrolled in clinical trials, a study of 67 children is a meaningful dataset that could support regulatory approval for this age group. All 67 children completing the study without treatment-related serious side effects is a reassuring finding.

What to keep in mind: This was an open-label study — meaning everyone knew which treatment was being given — with no placebo group, which is an acceptable design for this age and stage of research but does limit what conclusions can be drawn. The study lasted only 24 weeks, which is not long enough to determine long-term safety or whether better sweat chloride levels translate into healthier lungs years later. Standard breathing tests cannot be performed reliably in children this young, so functional lung outcomes could not be measured directly. The added sweat chloride reduction was measured against ETI, which is already a highly effective treatment, so the additional benefit, while meaningful, is measured from an already high baseline. The study was funded by Vertex Pharmaceuticals, the maker of both medicines, which is standard for industry-sponsored trials and does not by itself undermine the findings, but warrants acknowledgment. Longer follow-up and broader outcome measures are the clear next priority.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42710511/

---